Lupin rises on re-introducing Methergine Oral Tablets in US market

29 Apr 2016 Evaluate

Lupin is currently trading at Rs. 1593.00, up by 15.85 points or 1.00% from its previous closing of Rs. 1577.15 on the BSE.

The scrip opened at Rs. 1587.00 and has touched a high and low of Rs. 1594.75 and Rs. 1569.60 respectively. So far 9,953 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1594.75 and Rs. 1527.80 respectively. The current market cap of the company is Rs. 71,818.00 crore.

The promoters holding in the company stood at 46.52% while Institutions and Non-Institutions held 42.27% and 11.22% respectively.

Lupin and its US subsidiary, Lupin Pharmaceuticals, Inc. (collectively Lupin) have re-introduced Methergine (methylergonovine maleate) Oral Tablets 0.2mg for the prevention and management of postpartum hemorrhage (PPH).

Methergine is the only FDA-approved oral uterotonic and is a preferred oral agent in the management of PPH, according to guidelines issued by the American Congress of Obstetricians and Gynecologists (ACOG).

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×